Longwood Fund

  • About
  • Portfolio
  • Team
  • Press
  • Investor Login
  • Industry Events
  • About
  • Portfolio
  • Team
  • Press
  • Investor Login
  • Industry Events

BBOT Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types

June 16, 2025

In Conversation with Chris Loose, CEO and Co-founder of Progentos Therapeutics

June 11, 2025

Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025

June 6, 2025

Evommune Announces Top Line Data from Phase 2 Trial of EVO756 in Chronic Inducible Urticaria Demonstrating Robust Activity and Favorable Safety Profile

May 28, 2025

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics’ investigational novel conditionally activated IL-2 pro-drug WTX-124

May 27, 2025

Rectify Pharma to Present Translational Data on Novel Approach to Treat Chronic Kidney Disease and Vascular Calcification at ERA 2025

May 27, 2025
« Older Entries

Longwood Fund

The Prudential Tower

800 Boylston Street
Suite 1715
Boston, MA, 02199

  • About
  • Portfolio
  • Team
  • Press
  • Investor Login
  • Industry Events

© Longwood Fund. All Rights Reserved